A SINGLE-CENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS INJECTIONS OF LANREOTIDE AUTOGEL IN PATIENTS WITH ACROMEGALY PREVIOUSLY TREATED WITH OCTREOTIDE

作者：Kelly Phillip; Maher Kathy T; Chew Shern L; Monson John E; Grossman Ashley B^*; Jenkins Paul J

来源：Endocrine Practice, 2010, 16(2): 191-197.

DOI：10.4158/EP09184.OR

Objective: To evaluate the efficacy of lanreotide Autogel, a depot preparation of a long-acting somatostatin analogue, in patients with acromegaly who were previously treated with octreotide.
Methods: In a prospective single-center, open-label, comparative study, 13 patients were switched from octreotide treatment (baseline) to lanreotide Autogel therapy at a fixed dosage of 90 mg/4 wk. After 6 injections, the dosage was titrated to 60, 90, or 120 mg/4 wk, on the basis of growth hormone (GH) levels, for a further 6 injections. Mean GH and insulinlike growth factor-I (IGF-I) levels were determined at baseline, during treatment (to 48 weeks), and up to 8 weeks after the last injection.
Results: There was no significant change in the proportion of patients with GH and IGF-I control from baseline to week 48 (GH, 85% to 89%; IGF-I, 46% to 62%). Mean GH levels changed little from baseline, but mean IGF-I levels were significantly lower after 32 weeks (P<.05) and 48 weeks (P<.02). Data collected at 6 and 8 weeks after the last injection suggested that the efficacy of lanreotide Autogel can persist for longer than 4 weeks.
Conclusion: This small study suggests that lanreotide Autogel is at least as effective as octreotide in the control of acromegaly and may last for longer than the recommended 4 weeks. It appears to be a useful alternative to long-acting octreotide in the treatment of acromegaly. (Endocr Pract. 2010;16:191-197)

• 出版日期2010-4